A New Approach to an Old Problem: No Longer Just the Azoles for Candida

A New Approach to an Old Problem: No Longer Just the Azoles for Candida

World Class CME is accredited by the Accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. World Class CME designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Scynexis, Inc.

Audience:  This activity was planned for obstetricians and gynecologists, advanced practitioners in women's health, as well as primary care providers in women’s health.

PROGRAM DIRECTOR

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University School of Medicine
Director of Gynecological Ultrasound
Co-Director of Bone Densitometry and Body Composition
Department of Obstetrics and Gynecology
New York University Medical Center
New York, New York

AUTHOR

Learning Objectives
At the conclusion of this activity, the participant will be able to:

1. Appreciate the scope of the problem of candida infection in terms of cost, lost productivity, and medical visits
2. Learn current diagnostic and treatment patterns for vulvovaginal candidiasis
3. Appreciate the attributes of the new antifungal class (Triterpenoid) for vulvovaginal candidiasis
4. Analyze clinical trial with the non-azole approach to vulvovaginal candidiasis

Date of Original Release: May 15, 2022          Date Credits Expire: May 14, 2025

CONFLICT OF INTEREST DISCLOSURE

Steven R. Goldstein, MD
GYN Advisory Board:  Scynexis, Inc.

Mark Spitzer, MD
Consultant: Scynexis, Inc.

All of the relevant financial relationships for this faculty have been mitigated

NO DISCLOSURES TO DECLARE
Heidi M. Wilson, Course Director